Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2025-10-22 Proxy Solicitation & In…
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i Alligator Bioscience AB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice ('Kallelse') for an Extraordinary General Meeting (Extra bolagsstämma) for Alligator Bioscience AB. It contains the agenda, proposals for board decisions (such as capital reduction and share issues), and instructions for shareholders to participate. This falls under the category of materials sent to shareholders to provide information and request votes for meetings.
2025-10-22 Swedish
Notice of extraordinary general meeting in Alligator Bioscience AB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Extraordinary General Meeting' for Alligator Bioscience AB. It contains the agenda, proposed resolutions (including amendments to Articles of Association and rights issues), and instructions for shareholder participation. This type of document is classified as a Proxy Solicitation & Information Statement (PSI) because it provides shareholders with the necessary information to vote on specific corporate actions at an upcoming meeting.
2025-10-22 English
Alligator Bioscience carries out a rights issue of units of approximately SEK 120 million and raises bridge loans
Capital/Financing Update Classification · 1% confidence The document is a formal announcement by Alligator Bioscience AB regarding a proposed rights issue of units (shares and warrants) to raise approximately SEK 120 million. It details the purpose of the capital raise, the terms of the issue, subscription undertakings, and the need for shareholder approval at an upcoming extraordinary general meeting. This fits the definition of a 'Capital/Financing Update' as it describes a specific fundraising activity and changes to the company's capital structure.
2025-10-22 English
Alligator Bioscience genomför en företrädesemission av units om cirka 120 MSEK samt upptar brygglån
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience announcing a rights issue (företrädesemission) of units (shares and warrants) and the procurement of bridge loans. It details the terms, background, and motives for the capital raise, including shareholder subscription commitments and guarantees. This falls under the category of capital and financing updates.
2025-10-22 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding (a sale) by Avanza Bank Holding AB in Alligator Bioscience AB, specifically noting that the shareholding has crossed a threshold (10%). This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2025-10-17 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding by Nordnet AB in Alligator Bioscience AB, specifically crossing a threshold (5%). This is a standard regulatory disclosure for major shareholding notifications.
2025-10-14 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.